Bulls And Bears Of The Week: Apple, Chevron, FedEx, Uber And More

Bulls And Bears Of The Week: Apple, Chevron, FedEx, Uber And More

The escalating trade war with China continued to overshadow the markets in the past week. Furthermore, investors also saw mixed economic numbers, as well as positive surprises in quarterly reports and initial public offerings, bad news for a market darling from the Supreme Court, and fresh news for whale watchers.

As usual, Benzinga continues to examine the prospects for many of the most popular stocks with investors. Here are just a few of this past week's most bullish and bearish posts that may be worth another look.


In "Bank Of America: Apple Is Still An Innovator," Jayson Derrick takes a look at why one top analyst feels that the Apple Inc. AAPL era of innovation is far from over. Are investors guilty of underestimating the iPhone maker?

There seems to be significant expansion in the ways Alphabet Inc. GOOGL can make ad money, according to Dave Royce's "Deutsche Bank More Bullish On Google With New 'Blockbuster' Ad Possibilities."

"3 Reasons Goldman Just Added Chevron To Its America's Conviction List" by Wayne Duggan shows why one top analyst thinks Chevron Corporation CVX will be just fine after walking away from Anadarko.

Shanthi Rexaline's "Johnson & Johnson Analysts Laud Accelerating Pharma Business" reveals why analysts were impressed with the Johnson & Johnson JNJ review of its pharmaceutical businesses.

For additional bullish calls, also have a look at DA Davidson Remains Bullish On Lyft, Despite Weak Uber IPO Raising Concerns Over Ride-Hailing Model and Cowen Likes Ralph Lauren On A Pullback Despite Looming Tariffs.


In Wayne Duggan's "Short Sellers Already Piling Into Uber," see why short interest in Uber Technologies Inc UBER is already on the rise and likely to continue now that the company is in the red following its initial public offering.

ImmunoGen, Inc. IMGN got bad news from the FDA about a cancer treatment, sending its shares lower last week. So says "Here's Why Small-Cap Biotech ImmunoGen Shares Are Tumbling" by Shanthi Rexaline.

1 2
View single page >> |
How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.